applic technolog provid opportun radic chang di-
exposur variou end-market diversifi portfolio demonstr
initi coverag potenti game-chang diagnost
therapeut outperform rate
agnost therapeut adapt technolog hold promis enabl
research commerci partner ultim clinician better diagnos
treat diseas done advanc compani made develop
technolog capabl sequenc interpret adapt immun system
opportun adapt front adapt formul commer-
cial strategi secur beachhead three key marketslif scienc research
current total address market billion diagnost current
billion drug discoveri current billion adapt
right royalti amount estim repres
billion opportun import note repres product
opportun near- intermediate-term view compani
give credit build top platform enter new area
set busi long-term success adapt success
research partner advanc initi diagnost product
remain enorm amount untap potenti compani technol-
ogi believ compani industry-lead collabor help valid
opportun execut potenti give ad confid outlook
valuat stock thought initi coverag outperform rat-
ing base adapt growth opportun near-term catalyst potenti
upsid revenu target uniqu asset valuat methodolog
take consider comp mix multipl dcf
risk risk consid get commerci viabl product im-
munosequenc guarante time advanc known
genentech collabor enorm potenti valu mileston
payment likelihood commerci success challeng major-
iti current revenu come research partner variabl quarterli
perform could occur valuat admittedli difficult place mean-
ing valu futur opportun
adapt corpor seek improv peopl live translat scale preci-
sion adapt immun system product help diagnos treat monitor diseas
compani look fulfil promis immune-driven medicin
collabor provid valid approach compani take
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect ob-
jectiv report report intend provid person invest advic opinion
recommend herein take account individu client circumst object need
intend recommend particular secur financi instrument strategi particular
client recipi report must make independ decis regard secur
content introduct stock thought
issu drive stock
concern risk
introduct immun system
use process product
adapt product end-market
brian weinstein cfa blair introduct stock thought
found adapt biotechnolog corpor seattle-bas compani though
profound chicago root focus advanc immune-driven technolog improv diagnosi
ultim outcom patient across varieti diseas adapt creat
seri technolog capabl examin character interpret compon
adapt immun system adapt immun system consist seri special cell
 cell detect fight antigen insid bodi use receptor cell
surfac call t-cell receptor tcr b-cell receptor bcr provid basic overview
later report
capabl adapt develop led product servic use academ
pharmaceut partner diagnost test detect monitor minim residu diseas
mrd blood cancer sever candid diagnost offer infecti diseas
autoimmun diseas cancer addit team work genentech develop cancer
therapeut use adapt technolog total repres market opportun man-
agement peg billion expand new product develop
consid invest case adapt view compani morph
healthcar technolog compani appli scientif inform technolog capabl
solv healthcare-rel issu method sequenc tcr team develop
remark repres foundat element need busi model succeed
believ commerci success adapt come compani partner
abl turn vast amount data sequenc inform drive diagnost
end compani meaning partner help massiv undertak ad
industri heavyweight machin learn genentech oncology-bas therapeut
partner help provid legitimaci stori concept otherwis would difficult
believ success long-term object adapt hold promis revolution-
ize healthcar meaning way believ potenti opportun combin
valuat space confid investor strong manag team
board fuel share higher june ipo price per share
far stock initi coverag outperform rate admittedli valuat
challeng stock hold enterpris valu billion go
make case stock inexpens believ combin open-end
growth opportun team variou near-term catalyst potenti upsid revenu
target particularli compani clonoseq product uniqu busi
strong manag team board director potenti adapt acquir
near-term event consid help get us comfort premium valuat
place stock
term valuat use combin methodolog frame analysi
conced much valu come futur opportun analysi allow upsid
show even current level
report offer invest thesi risk stock provid color compani
technolog detail compani exist potenti end-market outlin financi assump-
tion discuss valuat consider
billion drug discoveri
billion person product
billion share product
billion earli detect
billion celiac diseas
billion ovarian cancer
billion global mrd monitor mm cll nhl
unit state
outsid unit state
billion life scienc research
million differ gene adult versu gene static human genom
million tcr blood healthi individu
possibl receptor combin immun repertoir
billion uniqu tcr bcr sequenc adapt
diseas specif tcr clonal expand patient blood present averag
less cell cell
adapt right billion character immun receptor
academ research use immunoseq
biopharma custom incorpor immunoseq clinic trial
clinic trial use immunoseq sinc
million live cover payer clonoseq three privat
healthcar system order clonoseq
nccn center order clonoseq
biopharma compani use clonoseq clinic trial
million newli diagnos surviv patient world-wide lymphoid malign
cancer cell cell
clonoseq detect capabl find diseas specif immun cell
current use on-going prospect investigator-l clinic trial mrd data
includ peer-review journal
target tier tier account account market potenti
metastat patient tumor type least one antigen may
priorit collabor
genentech million cash front billion mileston signific royalti
contain billion immun receptor right billion
identifi character differ stage uniqu antigen-specif
tcr differ clinic relev target
peer-review public date total high-impact journal
nejm natur cancer
patent applic file issu patent
royalti rate fred hutch net sale licens product
brian weinstein cfa blair issu drive stock
expound invest thesi import mention key issu believ
like affect stock perform next month section
critic resourc investor base valuat long-term opportun
sinc mani item give inform advanc project
ipo dilig discuss team meet investor roadshow
one routin ask question would take move stock higher
share settl follow initi offer view question common
mani investor less concern quarterli near-term revenu growth next
month updat develop pipelin product
abil fuel long-term opportun
given feedback share belief take move share higher event
revenu line expect list product-level mileston catalyst along
respect expect time believ execut step list exhibit
scorecard investor use pipelin develop key lever
move share upward
issu drive stock
year-end
submit data fda year-end add
blood valid sampl type label
bring first indic fda
continu signal valid
select first indic expect
submiss share product
year-end
first discuss fda
fourth quarter
ind submiss
fourth quarter
bring fda year-end
potenti catalyst unknown time
next year launch clonoseq ivd kit market ou
tbd initi develop next gen sampl type agnost ruo kit research
tbd explor partnership dx compani ou expans
tbd seek expans recommend includ addit time point
diseas state incorpor clonoseq specif data
exhibit point sever key mileston next sever quarter
believ critic includ
submit data fda add blood valid sampl type clonoseq label
submit chronic lymphocyt leukemia cll indic file clonoseq
submit first indic fda immunoseq dx
brian weinstein cfa blair adapt develop seri uniqu capabl allow decod translat
work genentech select first indic share therapeut product
submit investig new drug ind applic first share product end
fourth quarter
massiv adapt immun system adapt technolog hold promis enabl
research commerci partner ultim clinician better diagnos treat diseas
done advanc compani made develop technolog capabl
sequenc interpret adapt immun system
adapt immun system uniqu capabl diagnos treat diseas prior
adapt innov power system could har technolog
adapt develop compani abl read genet code adapt immun system
use diagnos fight diseas insid bodi everi singl minut everi singl day
immunosequenc cornerston adapt process repres major break-
led compani format immunosequenc name impli involv
sequenc via equip immun system provid raw data
immun system seen current see fight diseas
adapt idea tri decod languag adapt immun system
feasibl especi kind scale chang dr harlan robin adapt co-found
chief scientif offic team immunologist fred hutchinson cancer research cen-
ter develop new way accord compani key process involv
process hybrid sequenc rearrang tcr determin sequenc million
rearrang tcr gene
insight gain compani immunosequenc capabl captur adap-
tive ever-expand clinic immunom databas form reservoir compani
machin learn comput biolog expertis use find signatur diseas gain
access code immun system use develop therapeut fight enemi
adapt advanc product enabl clinician move beyond diagnosi base
sole biolog diseas precis incorpor precis view
host immun system respond intrud
moreov progress compani innov limit coupl ap-
plicat promis lie ahead enorm lay next section suc-
cess adapt would abl diagnos multipl diseas simultan typic blood
draw includ infecti diseas autoimmun diseas perhap importantli variou
cancer top compani work collabor partner genentech use
adapt immun system develop truli person therapi fight cancer overal
compani technolog potenti revolution diagnost therapeut
scale wit far
portun follow critic scientif achiev discuss adapt formul
commerci strategi secur beachhead key market estim repres
billion opportun import note repres product opportun
exposur variou end-market diversifi portfolio demonstr adapt op-
brian weinstein cfa blair near- intermediate-term view compani give credit build
top platform enter new area within three end-market think like
renov chicago histor soldier field wrigley field bone place
opportun expand around within area
specif adapt product target life scienc research clinic diagnost drug discoveri
provid plethora opportun product develop product intend probe
three market differ stage commerci develop believ
categori repres appropri mean describ adapt focus
support long-term confid busi
life scienc research adapt first enter commerci realm began sell im-
munoseq product academ biopharmaceut research occur becam
known compani creat product could sequenc immun system scale
seen custom life scienc use still use compani immuno-
sequenc capabl look answer translat research question discov new
prognost diagnost signal use inform unlock immun system
research project
date market fuel much compani revenu view immunosequenc-
ing technolog launch pad adapt commerci advanc ambit
thu life scienc may especi larg market import one consid
key relationship biopharmaceut compani use compani technolog
potenti bigger opportun develop
manag peg market adapt product life scienc billion annual oppor-
tuniti compos million academ research million biopharma-
ceutic compani work oncolog autoimmun infecti diseas believ
million biopharmaceut market expand especi given grow preval
compani mrd product clonoseq use clinic trial discuss increas
access awar immunosequenc field
clinic diagnost total address market estim billion clinic di-
agnost second-largest opportun manag team see platform
compani would thrill total dollar market opportun midteen bil-
lion adapt tip iceberg sinc incorpor near-term product
indic goe well would repres sliver possibl total market
discuss manag aggress work fulfil promis opportun
indic product
clinic diagnost incorpor two area mrd monitor earli detect first
mrd monitor come compani first clinic product clonoseq product look
number malign cancer cell patient across multipl period monitor treatment
success check recurr compani technolog oper level accuraci
time greater current standard flow cytometri today clonoseq fda approv
monitor mrd bone marrow sampl patient multipl myeloma mm acut lym-
phoblast leukemia within next sever year team believ also expand
indic includ chronic lymphocyt leukemia cll non-hodgkin lymphoma nhl
also expand use blood instead bone marrow
brian weinstein cfa blair combin indic allow compani target major million newli diag-
nose surviv patient lymphoid malign monitor therapeut success
recurr therefor includ entir group mrd monitor estim
billion made billion billion outsid unit state
addit clonoseq compani work develop second clinic diagnost immu-
noseq dx believ reach market product aim use compani
develop tcr-antigen map develop collabor map
trillion tcr million antigen map becom fill opportun
actual read adapt immun system simpl blood draw diagnos
idea immunoseq dx base knowledg adapt immun system per-
fectli tune diagnost cell recogn diseas immedi adapt could find way
decod cell respond diseas would abl identifi anyth
bodi seen see concept univers diagnost repres one largest op-
portun healthcar hard overst transform natur could
popul health success simpli put massiv commerci opportun
given specif diseas area publicli confirm immunoseq dx adapt
use repres indic estim address market includ earli detect
ovarian cancer high-risk women celiac diseas symptomat high-risk individu
difficult diagnos earli stage desper need non-invasive
diagnost base compani estim high-risk individu indic manag
believ opportun indic billion expect addit indic
ad tcr-antigen map fill boost market opportun multipl
drug discoveri third market compani explor largest accord manag
consist opportun compani collabor genentech develop
cellular therapi oncolog compani pursu two pathway develop novel
immunotherapi base tcr screen adapt initi product use off-the-shelf
tcr identifi cancer antigen common among patient
longer term compani hope use platform enabl develop person
brian weinstein cfa blair product use patient-specif tcr identifi real time risk say twice
come product pipelin promis type product overst
acknowledg still like year away commerci viabil
compani believ share product market billion interestingli
greater entir clinic diagnost market compani target initi indic
clonoseq immunoseq dx person product market valu billion
time manag believ person market larger share market
given share product along develop compani believ right
share opportun greater
view assumpt behind obviou area busi
discuss importantli billion market figur base total drug sale
adjust royalti rate adapt would get revenu stream moreov
estim drug discoveri market consist product develop
genentech agreement adapt control right develop tcr cellular therapi area
outsid oncolog autoimmun infecti diseas well vaccin go
path market size could increas rather larg amount
 research
collabor provid valid compani approach set busi
long-term success adapt success research partner ad-
vanc product mrd analysi remain enorm amount untap potenti
compani technolog unfortun real-tim access progress team
make imposs us know larger opportun come fruition
believ howev compani industry-lead collabor help valid tech-
nolog approach adapt pursu give us ad confid outlook
describ believ main collabor genentech bring invalu
assist critic area compani long-term ambit bring clinic product
pipelin fruition
first major collabor adapt seven-year agreement ink
decemb relationship involv use research machin learn
technolog develop tcr-antigen map decod ring make diagnost
product develop early-stag detect even possibl
brian weinstein cfa blair agreement call appli machin learn comput statist
compani immunom databas raw data gener immunosequenc al-
low map tcr sequenc antigen design fight right data
model diagnost product develop come result work done
parti stay adapt exchang adapt use microsoft azur cloud servic
standard volum price guarante minimum disclos tell
addit product develop relationship host azur
view critic import relationship sinc without use servic
compani capabl like character data compani gener
turn inform would possibl scale encourag microsoft
made equiti invest adapt work compani endeavor
second collabor genentech major therapeut compani own roch
deal sign decemb focus acceler develop commerci
t-cell therapi treatment broad rang tumor type sever compon
arrang although essenc adapt use technolog screen
identifi character tcr believ directli target specif cancer antigen includ
neoantigen newli form antigen may easier detect attack take place
genentech respons take target develop clinic trial pathway han-
dling regulatori matter commerci product
adapt receiv million up-front payment roch februari
anoth billion avail form mileston payment addit fund becom
avail upon complet negoti develop million regulatori million
commerci mileston billion addit capit royalti
commerci sale product develop part collabor adapt may abl
record revenu futur royalti rate rang anywher single-digit percent-
age revenu share product high-teen percentag revenu person
product meaning sourc revenu futur
mere agreement cours inform likelihood success believ
billion commit roch strong signal belief technolog adapt de-
velop use develop manufactur therapeut oncolog
bullish long-term opportun risk consid evalu-
ate invest adapt highlight
first compani pioneer novel approach sequenc adapt immun system
gener commerci viabl product technolog certainti fulfil promis
compani technolog team must abl turn vast amount data collect
immunosequenc process inform requir tremend amount expertis
machin learn comput biolog believ team challeng
time success unknown unpredict make model revenu overal
financi profil compani difficult know product may come
work compani product gener revenu
concern risk
brian weinstein cfa blair second genentech collabor enorm potenti alter opportun adapt
drastic uncertainti consid name either off-the-shelf tcr patient-
specif tcr discov path commerci adapt control sinc
genentech charg advanc clinic trial regulatori interact reimburs
ultim commerci product cours case diagnost op-
portun even know product go develop time market
price inform add challeng model busi adapt
opportun cash billion futur mileston payment genentech time
specif trigger remain unknown time make
third present vast major revenu gener partnership aca-
demia pharmaceut custom revenu custom gener tie
contractu agreement time revenu hit may slip quarter quarter
mean potenti short-term volatil result versu analyst expect
although happen full-year target would like affect
lastli conced make valuat case stock challeng compani adap-
tive compar nearli record valuat level unlik sustain
longer term concern event even necessarili relat adapt
could quickli chang sentiment space caus valuat suffer meaning correct
addit valuat methodolog describ later report base near-term
revenu cash flow rather depend success opportun fulli assess
point use probability-bas approach think driver acknowl-
edg approach base educ guesswork other may take umbrag
methodolog assumpt
adapt found two brother northern suburb chicago came
togeth form busi design captur messag within adapt immun system
today adapt oper lab corpor headquart seattl
square-footage lab south san francisco full-tim employeesrep-
resent signific amount progress sinc found year ago view adapt
one differenti growth stori come across two decad
cover name space led impress leadership team
section discuss compani leadership provid in-depth discuss im-
mune system adapt done har power within bodi
believ team adapt well posit make good opportun front
compani impress manag team believ strong board
director add confid compani prospect highlight street-
face member team
chad robin co-found chairman ceo along brother harlan robin chad robin
co-found adapt septemb move seattl chicago
accompani co-found compani mr robin held posit across medic technolog
brian weinstein cfa blair invest real estat compani impress develop strong
cultur abil bring massiv collabor across finish line build impress
support team board consist industri leader
harlan robin ph co-found chief scientif offic mention dr robin co-found
busi brother come key innov around immunosequenc-
ing techniqu would becom bedrock compani
impress serv variou role comput biolog program fred hutch
includ assist faculti member associ april
full member head program april june also worth
mention dr robin hold physic harvard univers master degre
ph physic univers california berkeley visit appoint
california institut technolog
moreov dr robin receiv postdoctor appoint particl theori group weiz-
mann institut scienc israel institut advanc studi princeton univers
princeton develop bioinformat algorithm micro ribonucl acid target bacteri
juli rubinstein presid ms rubinstein came adapt februari serv
varieti role includ chief busi offic head corpor busi develop
previous held variou world-wide commerci develop role oncolog divi-
sion primarili focus cancer immunotherapi ms rubinstein serv board truste
valeri fund pediatr oncolog organ new jersey new york hold
 harvard busi school dual undergradu degre wharton school
annenberg school univers pennsylvania
chad cohen chief financi offic chad cohen join adapt august serv
chief financi offic zillow group inc work sinc join zillow
mr cohen serv senior member financ team ticketmast entertain inc
previous serv board inc public pet insur
compani includ chair audit committe hold busi administr
boston univers
compani sever impress board member may known invest-
ment commun particular highlight kevin conroy chairman presid ceo exact
scienc corpor known mr conroy decad begin success
tenur ceo third wave technolog inc mr conroy prove adept scale organiza-
tion foster success cultur bring innov product market sign collabor
agreement work invest commun believ mr conroy skill
use chad robin team begin scale oper work rigor
public compani
addit believ investor like familiar dr michael pellini former chair-
man presid ceo foundat medicin acquir roch dr pellini
experi diagnost therapeut combin relationship industri leader
biopharmaceut compani investor bode well adapt believ pres-
enc board yet anoth exampl adapt stamp approv
industri best brightest
brian weinstein cfa blair point reader recogn adapt open door take peek insid
immun system led skill experienc leader mani may
mean whole lot make much sens given complex immun system
product adapt develop follow section attempt summar
mean adapt
introduct immun system
everi singl second everi singl minut everi singl day epic biblical-esqu battl
good evil wage battl life death clash fabric human
societi struggl million year make involv billion ye billion soldier
violent clash use variou trick techniqu get upper hand battl
fought thousand mile away report sever page deep daili
newspap much closer home war take place insid us compon
immun system work identifi target ultim kill invad antigen level
precis furi human-to-human conflict come close replic
stori adapt stori battl technolog develop help
home team maintain qualit militari advantag invad enemi dramat
ye real definit next coupl page hope explain basic
human immun system adapt innov approach look use languag
adapt immun system creat tool help win daili battl abl
better diagnos ultim treat diseas
understand compani tri accomplish set scene imagin
gang maraud murder look run wild across old town fieri dragon
swoop caus terror mediev castl bad guy case
bodi antigen like sheriff patrol town horseback gallant knight gallop
confront dragon immun system monitor fight pathogen time
immun system adapt immun system look detect
fight diseas adapt technolog aid summar
replica immun system
brian weinstein cfa blair immun system primer human bodi protect potenti infect ill
immun system system compris innat non-specif defens mechan adapt
pathogen-specif defens mechan compon underli function keep
bodi healthi prevent pathogen get bodi tri get rid anyth
recogn belong
innat immun bodi first line defens invad pathogen consist
epitheli barrier skin mucou membran white blood cell alway readi
protect kind invad part immun system abl deal
pathogen provid critic first line defens sophist weapon often
need protect bodi virul organ heavier pathogen load
adapt immun system come
name suggest adapt immun system adapt immun machineri respond
specif pathogen destroy adapt immun bring refin radar detect
smart weapon fight also memori previous encount pathogen
abl tap memori mount immun respons meet recogn
enemi vanquish
adapt immun effect cell special cell hold instruc-
tion diagnos treat diseas bodi present lifetim
diagnosi diseas done via receptor surfac cell abil
constantli rearrang abl recogn everi possibl pathogen exist result
number gene adapt immun system believ million compar
static human genom total healthi individu million
cell blood read genet code cell give abil detect
identifi invad cell involv respons cell bind antigen
replic attack invad presenc addit kill directli cell involv
send chemic signal help produc weapon foreign bodi help cell
make antibodi primari function cell antibodi creat cell stop pathogen
alert bodi make therapi kill intrud alert patrol defend cell call
phagocyt engulf kill antibody-cov intrud like bomb strike paint target
immun system identifi kill invad presenc retain memori enemi
specif abil quickli identifi kill return
abl identifi creat right instruct kill pathogen adapt
immun system simultan perfect diagnost therapeut way get
code system use perform function would obvious lot valu
abl diagnos diseas earli creat therapeut aid immun system respons
adapt biotechnolog corpor partner come
adapt proprietari immunosequenc technolog call immunoseq provid insight
individu collect immun respons level compani said possibl
previous today immunoseq core compani effort use academ
biopharma custom basi adapt avail product detect mrd variou
blood cancer date use academ research
biopharma compani incorpor clinic trial
use process product
brian weinstein cfa blair sequenc cell taken place provid raw data adapt
immun system necessari decod data map cell specif antigen
done use combin assay call multiplex identif t-cell receptor antigen
specif mira meaning amount machin learn mira platform look
simultan map million tcr thousand specif antigen provid
insight diseas someon expos fight run assay adapt
pool antigen interest incub immun cell mani differ donor see
cell respond languag speak order react respond
antigen
map process complet either directli via compani collabor
use proprietari comput model machin learn creat tcr-antigen
map combin technolog allow perform scale time sensit
method success compani use inform gain basi
diagnost product brand immunoseq dx line product eventu becom
broad diagnost could simultan allow detect multipl diseas singl
technolog describ far repres compon necessari compani diagnost
capabl develop tcr-mediat cellular therapi addit technolog adap-
tive bring bear begin understand import recogn t- b-cell
receptor y-shape genet code interest therapeut purpos
chain receptor locat two differ chromosom
moreov immunosequenc inform structur pair individu
inform two pair belong togeth full pictur need
reconstruct receptor therapeut capabl overcom team develop
combinatori strategi take seen one receptor chain match
chain look like scale possibl tradit single-cel sequenc
technolog use call pairseq addit pair tcr pairseq also use
bcr improv antibodi develop engin
sequenc map pair taken place compani trutcr capabl
set motion goal identifi variou characterist pair tcr better
identifi therapeut grade pursu develop tcr-mediat
note compani platform provid long-term advantag creat clinic immu-
nomic databas billion immun receptor adapt data right
billion databas bedrock develop compani variou diagnost
therapeut product reli collabor appli machin learn
dramat improv abil deriv insight databas use insight
product develop project diagnost therapeut compani intend map
one quadrillion tcr thousand clinic relev antigen view constant evo-
lution tcr-antigen map meaning part stori suspect investor may
adapt target three uniqu segment technolog life scienc research clinic
diagnost clonoseq immunoseq dx drug discoveri provid overview
compani intent market discuss progress made date
adapt product end-market
brian weinstein cfa blair life scienc research life scienc research market compani commerci
immunoseq servic kit research use ruo product adapt first
foray commerci set earli part decad sale research
biopharmaceut compani still repres signific portion revenu product
custom attempt help answer translat research question discov new prognost
diagnost signal use inform unlock immun system
immunoseq foundat everyth adapt built last year product
use multiplex bias-control pcr basi extract inform abl accur
quantit sequenc million immun receptor directli dna also
level high-throughput previous attain complet data sequenc-
ing inform upload immunoseq analyz allow user studi properti
dynam frequenc abund view find visual form entir
packag sampl process visual data allow custom
easili access inform previous avail adapt therefor believ becom
global standard immunosequenc
date immunoseq commerci success use academ
research biopharmaceut compani incorpor technolog
clinic trial believ adapt penetr market begin
low singl digit percentag basi next sever year believ
research learn capabl interrog read immun system
bode well growth addit adapt immuneaccess databas allow research
use platform share data publicli review peer-review manuscript sub-
mission abil openli collabor show find act mean fuel fire
grow awar around immunoseq
manag big ambit immunoseq world-wide standard immunosequenc-
ing accomplish team outlin four step increas penetr market
becom master believ includ
offer clinical-grad research product adapt work analyt valid im-
prove version research data use clinic valid potenti diagnost
deepen relationship exist custom compani intend expand late-stag
clinic trial diseas state beyond oncolog
creat ubiqu broad global reach manag seek world-wide distribut
partner broaden reach product
develop accredit program high-complex lab run immunoseq manag
consid partner high-complex lab run sequenc portion immunoseq
broaden inclus product nonregistr clinic trial
immunoseq open expect continu open door collabor new
product life scienc research also across sever market discuss
therefor life scienc research unlik major driver share believ inves-
tor keep eye progress sinc bedrock pipelin
clonoseq build immunoseq foundat life scienc research set adapt
beachhead clinic diagnost came launch clonoseq product target detect
monitor mrd lymphoid malign said differ determin number
malign cell cell blood cancer allow distinguish whether
number malign cell decreas increas help determin therapi probabl
relaps
abl see count cell extrem import product clonoseq much
sensit current standard flow cytometri specif product accur detect mrd
sensit compar current accept standard
depend cancer type allow adapt
detect recurr much sooner enabl therapi restart faster hope lead better
outcom sensit product evid sever clinic valid studi form
basi product approv believ superior tradit flow cytometri
could larg reason potenti share win time
get specif technolog clonoseq report believ workflow
import concept investor grasp sinc help financi model discuss
physician order test adapt patient bone marrow sampl ship
seattl lab upon receipt sampl patient report return order physician
within day receiv fresh specimen day store specimen report two
form clonal id report sequenc domin clone sequenc track
mrd report longitudin graph show level mrd time allow comparison
mrd see whether diseas increas decreas patient
view launch clonoseq come excit time cancer treatment mrd monitor
increas import blood-bas cancer treatment exampl nation comprehen-
sive cancer network nccn guidelin includ mrd valid test assess burden
respons treatment mm treatment stage addit recent year new
therapi come market type cancer result increas surviv rate
mean patient monitor requir longer period open possibl
mrd surrog primari endpoint therapeut clinic trial increas power
sensit great like better predict patient outcom total compani
believ testabl popul unit state patient
given chang way clinic commun view mrd test therapeut op-
portun allow believ clonoseq technolog advantag could allow signific
market share gain end product market sinc receiv
fda approv use sampl bone marrow patient multipl myeloma mm acut
lymphoblast leukemia sinc launch order nearli healthcar system
institut nccn center unit state use on-going prospect
investigator-l clinic trial includ peer-review public
reimburs current approv indic also progress nice compani
million live contract number includ three larg nation payer
well januari grant posit coverag decis medicare-elig
mm patient decis includ up-front reimburs level
cover entir patient treatment episod gener id report track mrd report
discuss reimburs financi section
brian weinstein cfa blair move forward clonoseq sever growth driver help support
revenu compound-annual-growth-rate lever includ
expans addit indic product along posit reimburs
decis compani plan submit data fda cll follow nhl
combin two indic repres billion total clonoseq address
market billion
valid approv use blood sampl type detect compani ex-
pect submit data add blood valid sampl type believ would
expand util test consid sampl type current standard care
much less invas gather bone marrow
develop commerci ivd kit allow decentr test run
time bit uncertain launch unit state expect three-
five-year timelin laid launch kit intern market
immunoseq dx immunoseq dx leverag compani core immunoseq sequenc technol-
ogi grow clinic immunom databas machin learn capabl compani
intern via collabor partner expand tcr-antigen map map
tri link trillion tcr million antigen intent use inform
clinic set univers diagnost abl find diseas earliest stage
immunoseq ideal suit sinc tcr immunoseq character
constantli scan environ sign pathogen one key function tcr
detect diseas earliest point immedi clonal expand respond fight
antigen thu compani continu expand understand tcr interact
diseas abil construct ever-increas diagnost possibl
eventu compani goal use immunoseq dx abl read nearli entir
immun system allow clinician read immun system see
real time thu improv outcom tackl diseas sooner specif
current diagnost method allow
current diagnost techniqu limit often requir diseas present
detect presenc antigen often limit detect one diseas time adap-
tive technolog theoret capabl see diseas minut level also capabl
look mani diseas simultan addit team use retrospect
sampl machin learn improv perform expand target valu
immunoseq dx grow time
initi focu immunoseq dx broad popul screen rather earli de-
tection specif autoimmun oncolog infecti diseas meet follow criteria
clinic relev antigen known understood
high unmet need diagnosi
opportun improv patient outcom identifi diseas earli stage allow
earli intervent take place
avail sampl set known patient outcom diseas easili
ad menu
brian weinstein cfa blair expect hear initi target immunoseq dx platform end
compani provid insight like candid name
commentari compani file suggest team preliminari data celiac diseas
ovarian cancer
compani tri identifi confirmatori clinic signal diseas year
submit fda review constant stream addit diseas ad
platform tcr-antigen map built would constantli improv valu
product howev base initi indic mention adapt believ target
annual market opportun stagger billion made celiac diseas test-
ing billion ovarian cancer screen billion
celiac wind initi target believ immunoseq dx would perform annual
individu two first-degre rel confirm celiac diagnosi
undiagnos gi symptom current standard care diagnos celiac diseas blood test
target specif antibodi posit would result confirmatori biopsi
small intestin along invas natur biopsi perform biopsi useless patient
alreadi follow gluten-fre diet need reintroduc gluten effect
biopsi workup surprisingli given gauntlet test invas natur biopsi
gut mani peopl go forward compon tradit test
celiac diseas foundat estim affect world-wide celiac diseas
peopl first-degre rel suffer celiac diseas chanc also
diseas patient along undiagnos gi symptom result
signific demand celiac test underscor demand celiac test today
time peopl test diseas actual wind definit diagnos
stat help form basi target market roughli million patient unit
state compani target
signific awar issu among patient assum uptak would
steadili move higher believ manag long-term penetr target
market unreason term near-term target revenu model
test though repres million scale million
assum reimburs fraction expect list price test
ovarian cancer immunoseq dx use high-risk patient diagnos treat breast
cancer brca mutat intent run test least annual
popul present test earli detect high-risk patient underscor
need offer provid confid reimburs coverag matricul
time accord breast cancer research foundat million breast cancer
survivor unit state furthermor nation cancer institut estim roughli
women brca genet mutat combin market million
women unit state alon could screen least one time per year
unlik celiac diseas driven patient experienc pain symptom believ
awar ovarian screen take longer develop among patient sinc women
know brca statu dynam reflect long-term market penetr rate
like celiac diseas test revenu model test
though repres million scale million mention
celiac test assum reimburs fraction list price test
brian weinstein cfa blair worthwhil point earli indic immunoseq dx
list price notion price get complex capabl offer provid
continu increas compani seem set yet play although
addit test opportun drive list price immunoseq dx higher model
assum first two indic mention get market dynam
come play someth need eventu address incorpor
long-term revenu build believ compani expect wind
immunoseq dx nowher near near-term
input model
drug discoveri given massiv divers immun receptor follow tcr exist
antigen tcr identifi amplifi control particular
diseas end adapt seek use capabl identifi tcr match
antigen help diagnost also form basi immune-medi therapi
varieti end-market notabl oncolog
date result seen proof concept natur follow compani
rigor process advanc therapi specif team look tcr occur low
frequenc healthi individu character bind avid strong
bind antigen cytotox potenc file team report
identifi character antigen-specif pair tcr target
determin move forward team use seven-step process evalu
tcr seven step look good compani would look construct ind packag
decemb genentech adapt announc collabor licens agreement
use process develop manufactur commerci novel neoanti-
gen direct t-cell therapi cancer patient agreement spell invest
thesi report high level use adapt technolog product develop
genentech capabl advanc product clinic trial reimburs
commerci genentech paid adapt million front opportun
addit billion come variou mileston addit royalti payment stem
commerci activ
partnership move two path product develop share model personal-
ize model share product pathway dna profil patient tumor sampl antigen
neoantigen character match tcr alreadi character
adapt trutcr librari effect marker healthi individu allow
compani deliv tcr whose tumor express share antigen librari
present two share product select librari tcr target cancer
antigen mani patient expect compani inform invest commun first
give idea move forward come month team look
move forward ind first share product estim result
launch initi discuss fda product expect take place fourth
quarter compani peg market share product billion
second path therapi complet person pathway still
interrog patient tumor dna look antigen neoantigen patient blood
also sequenc look tcr real time adapt technolog would use
screen tcr act patient-specif neoantigen tcr becom appar
would engin cell therapi creat patient-specif product deliv
patient inject
brian weinstein cfa blair liter mean cellular immunotherapi brian weinstein would engin spe-
cific neoantigen blood would uniqu differ therapi creat
manufactur andrew brackmann anyon els amaz stuff right wildli excit
far becom realiti say noth potenti commerci consider cost
manufactur one-off therapi reimburs notion deliv liter
definit person therapi worth keep track one compon
stori could lead massiv expans valuat play
think competit adapt difficult point one compani
work end-market adapt plan involv compani may
piec technolog work within end market review
space come across think much pure overlap
cours given massiv market adapt tri target well vast area within
healthcar compani aim fulli expect competit emerg one area
point time said view adapt strong first-mov advantag given
progress made date within research launch clonoseq clinic right bil-
lion immun receptor own patent also say noth strong manag
leadership team support compani
continu monitor potenti competit threat pop
point investor list potenti competitor compani outlin file includ
list compani well market target
invivoscrib inc irepertoir inc takara inc fluidigm corpor dolomit
brand blacktrac hold ltd
clonoseq variou laboratori perform flow cytometri in-hous particularli outsid
unit state well invivoscrib inc archerdx inc becton dickinson compani
immunoseq dx grail inc inc exact scienc corpor inc
nolog gmbh inc
note drug discoveri one area may direct overlap competit
cancer cellular therapi field intens competit area sever big pharma biotech
name game despit differ development strategi specif consid
competitor develop engin tcr-base therapi most-advanc program target
immat program provid initi proof concept use engin
tcr cell therapi may limit treat patient whose tumor express select
group common tumor antigen
howev addit compani work develop individu tcr therapi
base patient-specif antigen includ pact pharma
bluebird bio collabor given tcr therapi activ area
research oncolog believ addit competitor emerg adapt progress
collabor genentech toward identifi target therapi candid although adap-
tive new player oncolog drug develop believ compani extens technolog
profil adapt immun system combin genentech expertis develop new
adapt report revenu two differ line item sequenc revenu develop
revenu report structur unfamiliar us given compani report similarli
recent list gone public report like
note line item incorpor sever differ underli driver assump-
tion may difficult obtain granular inform dissect nonetheless attempt
dig deeper understand move growth segment discuss
sequenc revenu total revenu expect grow compound an-
nual rate compris sale sequenc servic immunoseq research
custom along clinic research test servic sale clonoseq date revenu
driven primarili sale immunoseq research biopharma partner addi-
tion clinic adopt clonoseq
move forward forecast period revenu line item also includ
revenu expand indic clonoseq well compani immunoseq dx pipelin
product discuss model assumpt immunoseq dx product expect
begin contribut modestli sequenc revenu begin
import note differ revenu recognit sequenc revenu segment
sinc vari custom product caus swing report quarterli revenu
research custom whose test run seattl lab contract gener includ
bill up-front advanc amount follow subsequ bill sampl result provid
up-front amount receiv record defer revenu revenu
subsequ record sampl result deliv
custom use ruo kit immunoseq product payment made adapt upon
deliveri kit amount record defer revenu sampl result
deliv custom revenu recogn proport estim sampl
report kit
clinic custom use clonoseq test revenu recogn clonoseq report
deliv revenu amount recogn variabl base circumst payer type
patient respons estim reimburs expect receiv payer
relat recent medicar coverag clonoseq monitor mm
note coverag decis state compani receiv per episod
treatment compani bill medicar amount deliv first
elig test result bill inclus entir patient treatment cycl four
test per patient one initi sequenc identif test
initi entir amount place defer revenu test run revenu
reclassifi onto incom statement break medicar volum
note revenu recognit would mean averag medicar patient asp
model per sampl run total divid four
develop revenu total revenu expect grow compound
annual rate deriv profession support activ servic bio-
pharmaceut compani use immunoseq clonoseq servic develop activ
exampl servic includ regulatori support respect adapt technolog
use product seek approv develop analyt plan sequenc data
particip joint research committe assist complet regulatori submiss
perhap importantli segment also includ revenu relat regulatori develop
commerci mileston associ genentech collabor
seen compani offer similar servic biopharmaceut custom
revenu stream tend lumpi sinc includ mileston difficult predict time
sometim outsid control compani dynam larg reli man-
agement estim revenu stream given specif agreement gener publicli
discuss success rate achiev mileston difficult predict still
discuss manag disclosur defer develop revenu believ
revenu stream model conservat repres area upsid could develop
base sever new product launch expand indic use broader payer adopt
potenti broader shift toward gener use platform technolog project
revenu compound-annual-growth-rate view base-cas target see
path upsid report segment discuss
sequenc revenu believ best way forecast sequenc revenu break
line item three major constitu research revenu includ research fee-for-
servic research partnership sequenc revenu clonoseq immunoseq dx howev
detail assumpt categori believ import note
inform revenu contribut item may explicitli provid
file thu requir signific amount estim mind number
view direct anyth
brian weinstein cfa blair research revenu research sequenc revenu driven two main area research
fee-for-servic research partnership revenu associ direct sequenc
sampl model break two separ near term believ
investor focus research fee-for-servic line sinc compani
provid annual quarterli volum allow investor estim revenu contribut
forecast underli assumpt input
shown biggest driver research fee-for-servic revenu model total
volum assum volum grow asp
disclos file increas annual basi time well
beyond research fee-for-servic revenu relat sequenc volum research
partnership bit black box assum sever contract per year phar-
maceut compani intend use sequenc servic pharmaceut research
partnership also revenu develop regulatori mileston
includ development revenu segment plan period
estim revenu bucket grow million million
total total sequenc research revenu increas million
million compound-annual-growth-rate
clonoseq driver clonoseq rel straightforward model price volum
volum provid file forecast purpos includ volum indic
give investor better idea think product launch among mm cll
nhl number unlik provid help gain better understand
build expect volum
model assum rapid uptak cll begin approv point
nhl approv although note compani
run sampl today even though approv
immateri amount volum near-term model indic
brian weinstein cfa blair beyond volum estim averag sell price obtain total revenu number
clonoseq next coupl year expect rang
per unit volum manag believ move toward coverag
per unit averag posit reimburs contract secur
model assum total blend asp clonoseq indic
lead us believ area upsid potenti model
addit revenu growth driver clonoseq lab volum compani also
plan launch clonoseq kit product run sequenc market outsid
unit state time uncertain compani said expect
next three five year model assum minim kit revenu begin
roughli kit run although believ could meaning revenu driver
outer year estim kit volum result kit revenu
million year would impli slightli less revenu per kit includ
clonoseq technolog run analyz adapt read data
use send client report
immunoseq dx believ immunoseq dx abil game-chang diagnost
launch diseas state critic need solut earli detect despit
potenti earli data readout look encourag take conserv approach
model revenu stream sinc product yet approv initi indic
final acceler volum difficult pinpoint
conserv framework mind model slight delay time market
slower volum ramp-up manag assum model assum first indica-
tion come market celiac diseas ovarian cancer sure manage-
ment provid specif volum indic believ forecast purpos
proper model volum per-incid basi shown assum rel
steep acceler volum period although assum rel
low asp per test factor littl way major reimburs win
total model immunoseq dx contribut million million
million million base sampl
upsid opportun overal model take modest discount manag long-term
sequenc revenu guidanc like alreadi factor conservativ therefor
believ area could act greater sourc upsid model includ
clonoseq cll nhl indic gain approv reimburs faster antici-
pate recal medicar reimburs per sampl run roughli model
call year rise
brian weinstein cfa blair clonoseq label chang includ blood valid sampl type sooner antici-
pate caus inflect volum
immunoseq dx approv come sooner reimburs higher
assum first sever year launch
addit immunoseq dx indic beyond celiac diseas ovarian cancer introduc
plan period
develop revenu line item tend lumpi base time recognit
revenu certain mileston on-going payment still could signific upsid
develop revenu estim partnership project progress success time
faster assum
model develop revenu made drug discoveri associ genentech
collabor addit mileston develop revenu biopharmaceut research
partnership includ sequenc revenu associ partnership
captur sequenc revenu discuss
genentech collabor revenu genentech collabor includ recognit
million per year million up-front payment essenti amortiza-
tion payment incom statement eight year mileston payment
includ agreement
given specif mileston respect payment amount known street
genentech control mani aspect collabor model take discount
compani achiev mileston payment specif incorpor delay
one year annual mileston payment model total incorpor
million mileston achiev next five year total billion avail
addit assum product approv time thu genentech royalti
revenu recogn
mileston develop revenu beyond genentech compani partnership
biopharmaceut compani use platform technolog product
drug discoveri develop effort littl known specif
partnership mrd develop agreement call take
conserv approach compani abil achiev annual goal revenu line
mention briefli segment descript investor mind quar-
terli swing report revenu focu annual number broader growth trend
one way track compani commerci progress beyond report revenu
defer revenu disclosur incorpor up-front payment receiv custom
anticip futur servic compani expect whether recogn
within next month beyond
discuss gross margin conced revenu pipelin develop much
import stori near intermedi term adapt still time
sure increas interest profit outlook compani unlik
case period forecast expens profit
neg
quick note defer revenu overlook
model compris gross margin dip
caus three factor addit new facility/capac end
unlik increas revenu meaning year one launch immunoseq dx
high cost good sold low revenu dollar earli inning
clonoseq cll nhl launch take time gather reimburs subsequ
year howev assum compani deliv volum revenu target see total
gross margin compani exceed
immunoseq long-term target
clonoseq long-term target
immunoseq dx long-term target
research develop primari activ relat develop
refin compani commerci assay immunoseq clonoseq invest
immun medicin platform includ immunoseq dx support valid discoveri work
therapeut develop work done part genentech agreement
relat histor project expens adapt compani spent
million compar million model beyond
year believ spend categori increas significantli dollar basi grow
compound annual rate compani work develop addit
indic approv product bring pipelin commerci stage
support trade-off near-term spend fuel pipelin believ
import note expens expect declin percentag revenu
forecast period go assum expens
sale market follow launch new product technolog sale market-
ing primari focu expect remain compani roll new product
expens relat expens line item consist primarili personnel-rel expens com-
mercial account manag market medic educ busi develop employe
well extern cost includ advertis custom educ market promot
spend market analys confer fee travel facil cost
respect commerci team end compani total full-tim
employe dedic sales/commerci activ time expect number increas
significantli immunoseq dx approv adapt choos control commerci
rather collabor establish lab larg extern commerci team believ
number could like multi-hundr sale profession decis commerci
solo partnership one expect dig bit believ investor
look board make-up idea way compani might choos go
model compani million sales-and-market expens
increas expens total million estim sales-and-market
spend million would repres dollar compound-annual-growth-rate
gener administr expens includ cost share-bas compens
personnel-rel cost employe execut legal financ account human resourc
administr function third-parti profession fee alloc facil cost
balanc sheet
compani amass million expens forecast million
plan period model spend million
repres dollar compound-annual-growth-rate
evidenc signific oper expens yet-to-b at-scal gross margin
revenu earli inning market penetr expect compani ebitda
posit near even intermedi term estim adjust loss interest tax
depreci amort million margin million
margin million margin
caveat genentech develop mileston nearli flow-through
ebitda event signific mileston reach quarter may fluctuat
quarterli ebitda margin investor mind analyz compani
quarterli basi
march adapt million cash cash equival million
short-term market secur base compani busi plan proce
recent sale common stock gener roughli million net proce
believ compani enough cash hand meet anticip cash requir
plan period per compani said current cash cash equival
market secur proce rais believ suffici fund oper
expens capit expenditur least month
anticip adapt becom profit end expect compani
continu burn cash throughout forecast period model includ signific
amount spend capit expenditur million million
support lab facil expans end cash market secur balanc
million million
valuationin term valuat cogniz nobodi mistak adapt valu name
rather high-octan big potenti opportun come big price tag understand
price tag accept howev gotten comfort base
combin methodolog describ
first look compani compar tabl realli ideal comp use
name hear often investor speak initi coverag
guardant octob initi coverag commercial-stag precis oncolog
compani outperform rate see guardant comp appropri given
opportun biotechnolog pharmaceut academ partner along
strong initi product clinic market therapi select late stage cancer massiv
long-term opportun success would creat massiv opportun fulli
encapsul current valuat liquid biopsi screen monitor cancer patient
adapt target opportun guardant present time paral-
lel term busi model progress pipelin seem hold term valuat
guardant trade time revenu addit use varieti life scienc
diagnost compani comp tabl basi think long-term multipl
use addit analysi describ
million
sourc factset william blair estim
beyond comp tabl also look discount cash flow model consid enter-
prise value-to-sal enterpris value-to-ebitda multipl assumpt dcf includ
probabl weight revenu build get us approxim billion revenu
almost come clinic diagnost life scienc sequenc develop
revenu genentech collabor long-term oper margin
genentech revenu come pre-tax margin tax rate discount rate
use ev-to-sal multipl time annual revenu dis-
count year back today averag discount valu across year multipl
time reflect mean forward revenu valuat comp group addit use
methodolog ev-to-ebitda use forward multipl time
weight dcf multipl analysi put weight revenu multipl
see critic compon futur valu deriv upsid current stock
price excess
thousand unless note
revenu report categori
thousand unless note
sale
research develop
sale market
gener administr
amort intang asset
total income/ expens net
provis benefit incom tax
fair valu adj seri convert prefer stock
net incom loss common sharehold
thousand unless note
cash equival
total cash equival market secur
prepaid expens current asset
properti equip net
restrict cash asset
accru compens benefit
current portion defer rent
accumul comprehens loss gain
total liabil convert prefer stock stockh
work capit report
prepaid oper expens
thousand unless note
flow oper
revenu
loss gain equip dispos
fair valu adjust convert pref stock warrant
chang work capit
prepaid expens current asset
account payabl accru liabil
total chang net work capit
oper
invest
purchas properti equip
proce sale equip
purchas intang asset
purchas market secur
proce sale matur market secur
invest
financ
proce issuanc common stock
proce exercis stock option
financ
increas decreas cash equival
equival begin period
equival end period
brian weinstein cfa blair price common stock public compani mention report follow
